Huapont Life Sciences Co Ltd Total Liabilities
Huapont Life Sciences Co Ltd total liabilities. Based on the latest financial reports, Huapont Life Sciences Co Ltd (002004) has total liabilities worth CN¥12.29 Billion CNY (≈ $1.80 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Huapont Life Sciences Co Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Huapont Life Sciences Co Ltd (2001–2025)
Total liabilities of Huapont Life Sciences Co Ltd from 2001 to 2025. This chart illustrates how Huapont Life Sciences Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Huapont Life Sciences Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Huapont Life Sciences Co Ltd Competitors by Total Liabilities
The table below lists competitors of Huapont Life Sciences Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Birchcliff Energy Ltd.
TO:BIR
|
Canada | CA$1.30 Billion |
|
Crayon Group Holding ASA
OL:CRAYN
|
Norway | Nkr16.59 Billion |
|
Sun Art Retail Group Limited
F:SRI
|
Germany | €35.40 Billion |
|
Del Monte Corporation
NYSE:DMC
|
USA | $1.36 Billion |
|
La-Z-Boy Incorporated
NYSE:LZB
|
USA | $1.03 Billion |
|
Xinxiang Chemical Fiber Co Ltd
SHE:000949
|
China | CN¥6.74 Billion |
|
Grainger PLC
F:1U4
|
Germany | €1.73 Billion |
|
Allient Inc.
NASDAQ:ALNT
|
USA | $281.63 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Huapont Life Sciences Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Huapont Life Sciences Co Ltd assets under control.
Liquidity & Leverage Metrics
Huapont Life Sciences Co Ltd Total Liabilities Ratios Explained
Huapont Life Sciences Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Huapont Life Sciences Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Huapont Life Sciences Co Ltd (2001–2025)
The table below shows the annual total liabilities of Huapont Life Sciences Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥12.05 Billion ≈ $1.76 Billion |
-13.79% |
| 2024-12-31 | CN¥13.98 Billion ≈ $2.05 Billion |
-1.17% |
| 2023-12-31 | CN¥14.14 Billion ≈ $2.07 Billion |
+4.97% |
| 2022-12-31 | CN¥13.47 Billion ≈ $1.97 Billion |
-5.25% |
| 2021-12-31 | CN¥14.22 Billion ≈ $2.08 Billion |
+0.93% |
| 2020-12-31 | CN¥14.09 Billion ≈ $2.06 Billion |
+5.20% |
| 2019-12-31 | CN¥13.39 Billion ≈ $1.96 Billion |
-2.97% |
| 2018-12-31 | CN¥13.80 Billion ≈ $2.02 Billion |
-12.61% |
| 2017-12-31 | CN¥15.79 Billion ≈ $2.31 Billion |
+16.78% |
| 2016-12-31 | CN¥13.52 Billion ≈ $1.98 Billion |
+45.42% |
| 2015-12-31 | CN¥9.30 Billion ≈ $1.36 Billion |
+18.68% |
| 2014-12-31 | CN¥7.84 Billion ≈ $1.15 Billion |
+115.56% |
| 2013-12-31 | CN¥3.64 Billion ≈ $531.96 Million |
+22.59% |
| 2012-12-31 | CN¥2.97 Billion ≈ $433.93 Million |
+84.93% |
| 2011-12-31 | CN¥1.60 Billion ≈ $234.64 Million |
+397.08% |
| 2010-12-31 | CN¥322.58 Million ≈ $47.20 Million |
+31.30% |
| 2009-12-31 | CN¥245.68 Million ≈ $35.95 Million |
-24.47% |
| 2008-12-31 | CN¥325.26 Million ≈ $47.60 Million |
-9.09% |
| 2007-12-31 | CN¥357.78 Million ≈ $52.35 Million |
+47.73% |
| 2006-12-31 | CN¥242.18 Million ≈ $35.44 Million |
+551.50% |
| 2005-12-31 | CN¥37.17 Million ≈ $5.44 Million |
-53.18% |
| 2004-12-31 | CN¥79.39 Million ≈ $11.62 Million |
-0.75% |
| 2003-12-31 | CN¥79.99 Million ≈ $11.71 Million |
-23.75% |
| 2002-12-31 | CN¥104.91 Million ≈ $15.35 Million |
+128.44% |
| 2001-12-31 | CN¥45.93 Million ≈ $6.72 Million |
-- |
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. It is involved in the production and sale of pharmaceutical preparations and raw materials. The company also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management… Read more